Table 1 Patients’ baseline characteristics.
N = 46 | |
|---|---|
Sex, n (%) | |
Female | 19 (41.30) |
Male | 27 (58.70) |
Age at admission (y), median (IQR) | 2.88 (0.92; 7.01) |
Infection severity estimates | |
Intensive care duration (d), median (IQR) | 3 (2; 5) |
Post-surgery admission, n (%) | 7 (15.22) |
Familial history of PID or similar clinical signs, n (%) | 2 (4.34) |
Familial consanguinity, n (%) | 3 (6.52) |
Relevant personal medical history, n (%) | 3 (6.52) |
Type 1 neurofibromatosis | 1 (2.17) |
Cystic adenomatoid pulmonary malformation | 1 (2.17) |
Rheumatoid purpura | 1 (2.17) |
Poor nutritional status before infection (weight ≤ -2SD), n (%) | 5 (10.87) |
Complete vaccination schedule, n (%) | 30 (65.22) |
DTP | 45 (97.83) |
13-valent conjugate pneumococcal vaccine | 42 (91.30) |
HBV | 42 (91.30) |
MMR | 43 (93.47) |
Meningococcal C vaccine | 32 (69.56) |
Positive PID screening score, n (%) | |
JMF | 0 (0.00) |
DSAI | 4 (8.70) |
CEREDIH | 5 (10.87) |
Time of follow up (months), median (IQR) | |
First follow-up consultation | 4.92 (3.40; 6.70) |
Second follow-up consultation | 23.40 (14.50; 28.23) |
